Formycon AG (ETR:FYB)
Germany · Delayed Price · Currency is EUR 23.80
+0.20 (0.85%)
At close: Feb 13, 2026
Formycon AG Employees
Formycon AG had 245 employees as of June 30, 2025. The number of employees decreased by 5 or -2.00% since the number was reported on December 31, 2024.
Employees
245
Change
-5
Growth
-2.00%
Revenue / Employee
€192,296
Profits / Employee
€660,688
Market Cap
420.41M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2025 | 245 | -5 | -2.00% | 245 | 0 |
| Dec 31, 2024 | 250 | 12 | 5.04% | 250 | 0 |
| Dec 31, 2023 | 238 | 33 | 16.10% | 238 | 0 |
| Dec 31, 2022 | 205 | 34 | 19.88% | 205 | 0 |
| Dec 31, 2021 | 171 | 40 | 30.53% | 125 | 46 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Fresenius SE & Co. KGaA | 177,356 |
| Bayer Aktiengesellschaft | 88,502 |
| Siemens Healthineers AG | 73,840 |
| Merck KGaA | 62,346 |
| RHÖN-KLINIKUM Aktiengesellschaft | 19,041 |
| Gerresheimer AG | 13,535 |
| MEDICLIN Aktiengesellschaft | 6,974 |
| Stratec SE | 1,420 |
Formycon AG News
- 4 days ago - EQS-News: Lotus Pharmaceutical becomes commercialization partner for Formycon's Keytruda biosimilar candidate FYB206 across major parts of the Asia-Pacific Region - Wallstreet:Online
- 4 weeks ago - EQS-DD: Formycon AG: Active Ownership Fund SICAV SIF SCS, sell - Wallstreet:Online
- 4 weeks ago - EQS-DD: Formycon AG: Active Ownership Fund SICAV SIF SCS, Verkauf • news - Onvista
- 7 weeks ago - EQS-News: FDA approves another interchangeable Ranibizumab Biosimilar, Nufymco – Strengthening US Presence with Zydus as Commercialization Partner - Wallstreet:Online
- 2 months ago - Formycon AG: Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda (Pembrolizumab), in the U.S. and Canada - Finanz Nachrichten
- 2 months ago - Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda (Pembrolizumab), in the U.S. and Canada - Wallstreet:Online
- 2 months ago - EQS-News: Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda (Pembrolizumab), in the U.S. and Canada - Wallstreet:Online
- 2 months ago - Formycon and MS Pharma sign exclusive commercialization partnership for Keytruda biosimilar candidate FYB206 for the MENA Region - Finanz Nachrichten